PPMO's as therapeutic modulators for myotonic dystrophy type 1

PPMO's as therapeutic modulators for myotonic dystrophy type 1

Bibliographic Details
Main Authors:	Holland, A, Varela, M, Klein, A, Raz, R, Arzumanov, A, Gait, M, Wood, M
Format:	Conference item
Published:	Wiley 2018

Similar Items

Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
by: Holland, A, et al.
Published: (2018)

Application of antisense conjugates for the treatment of myotonic dystrophy type 1
by: Stoodley, J, et al.
Published: (2023)

New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC).
by: Ashizawa, T, et al.
Published: (2000)

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
by: Klein, AF, et al.
Published: (2019)

Peptide-conjugated PMOs for the treatment of myotonic dystrophy
by: Stoodley, J, et al.
Published: (2022)

Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1
by: Marsh, S, et al.
Published: (2020)

Hearing impairment in patients with myotonic dystrophy type 2
by: van Vliet, J, et al.
Published: (2018)

The myotonic dystrophies: diagnosis and management.
by: Turner, C, et al.
Published: (2010)

Molecular genetics of myotonic dystrophy.
by: Barnes, P, et al.
Published: (1993)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
by: Overby, SJ, et al.
Published: (2022)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1--the patients' perspective.
by: Hilton-Jones, D, et al.
Published: (2012)

Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1 - The patients' perspective
by: Hilton-Jones, D, et al.
Published: (2012)

Alternative isoform regulation in myotonic dystrophy
by: Wang, Eric T. (Eric Tzy-shi)
Published: (2012)

Childhood-onset form of myotonic dystrophy type 1 and autism spectrum disorder: Is there comorbidity?
by: Angeard, N, et al.
Published: (2017)

Choroidal new vessels in type 1 myotonic dystrophy-related macular dystrophy respond to anti-VEGF therapy.
by: Zinkernagel, MS, et al.
Published: (2012)

Myotonic dystrophy: diagnosis, management and new therapies.
by: Turner, C, et al.
Published: (2014)

Preclinical development of antisense conjugates for the treatment of myotonic dystrophy 1
by: Stoodley, J
Published: (2024)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
by: Cerro-Herreros, E, et al.
Published: (2021)

Myotonic dystrophy: practical issues relating to assessment of strength.
by: Whittaker, R, et al.
Published: (2006)

Myotonic dystrophy--forgotten aspects of an often neglected condition.
by: Hilton-Jones, D
Published: (1997)

Clinical and molecular aspects of the myotonic dystrophies: a review.
by: Machuca-Tzili, L, et al.
Published: (2005)

Three cases of androgen-dependent disease associated with myotonic dystrophy.
by: Cooper, S, et al.
Published: (2003)

Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.
by: Talbot, K, et al.
Published: (2003)

Proteomic analysis of the function of DMPK, the myotonic dystrophy protein kinase
by: Luciano, Brenda Sierra, 1965-
Published: (2005)

Late-onset cytoplasmic body myopathy resembling myotonic dystrophy.
by: Morris, H, et al.
Published: (1999)

Positive effect of modafinil on daytime somnolence on patients with Myotonic Dystrophy
by: Talbot, K, et al.
Published: (2002)

Relationship between muscle impairments, postural stability, and gait parameters assessed with lower-trunk accelerometry in myotonic dystrophy type 1
by: Bachasson, D, et al.
Published: (2016)

A randomised controlled trial of modafinil for treatment of daytime somnolence in myotonic dystrophy
by: Talbot, K, et al.
Published: (2003)

Downregulation of the Glial GLT1 glutamate transporter and purkinje cell dysfunction in a mouse model of myotonic dystrophy
by: Sicot, G, et al.
Published: (2017)

Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy
by: Wagner, Stacey D., et al.
Published: (2017)

Using digital technologies to engage with medical research: views of myotonic dystrophy patients in Japan
by: Coathup, V, et al.
Published: (2016)

Incorrect diagnosis of myotonic dystrophy and its potential consequences revealed by subsequent direct genetic analysis.
by: Barnes, P, et al.
Published: (1994)

Therapeutic approaches for Duchenne muscular dystrophy
by: Roberts, TC, et al.
Published: (2023)

Design of a Bioactive Small Molecule That Targets the Myotonic Dystrophy Type 1 RNA via an RNA Motif–Ligand Database and Chemical Similarity Searching
by: Parkesh, Raman, et al.
Published: (2014)

Therapeutic approaches to muscular dystrophy.
by: Goyenvalle, A, et al.
Published: (2011)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011
by: Turner, C, et al.
Published: (2013)

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011.
by: Turner, C, et al.
Published: (2013)

DMPK and myotonic dystrophy : effects of CTG trinucleotide expansion upon DMPK and their contribution to DM pathogenesis
by: Davis, Brigid Michele, 1967-
Published: (2009)

NOVEL CELL PENETRATING PEPTIDES FOR SKELETAL AND CARDIAC MUSCLE DELIVERY OF PMO ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
by: Hammond, S, et al.
Published: (2011)

Enhanced serum immunoglobulin G clearance in myotonic dystrophy-associated hypogammaglobulinemia: a case series and review of the literature
by: Sasson, SC, et al.
Published: (2019)